Department of Internal Medicine, Hospital Universitari de Sant Joan, Institut d'Investigació Sanitària Pere Virgili, Universitat Rovira i Virgili, Reus, Catalonia, Spain.
Biomedical Research Unit, Hospital Universitari de Sant Joan, Institut d'Investigació Sanitària Pere Virgili, Universitat Rovira i Virgili, Reus, Catalonia, Spain.
Arch Med Res. 2018 Feb;49(2):119-122. doi: 10.1016/j.arcmed.2018.04.011. Epub 2018 Apr 24.
This study provides preliminary information on the usefulness of measuring serum paraoxonase-1 (PON1) concentration and activity (and other inflammatory markers) to predict tumor recurrence in patients with urinary bladder cancer. We studied a total of 39 hospitalized patients in whom the diagnosis of urinary bladder cancer was confirmed by transurethral resection. After five years of follow-up, 29 patients presented with tumor recurrence. As control subjects, we also studied 61 healthy subjects and a further 132 hospitalized patients who had a urinary catheter-related infection due to causes other than cancer. Results showed that urinary bladder patients had lower serum PON1 concentration and activity, and higher chemokine (C-C motif) ligand 2, C-reactive protein, and procalcitonin concentrations than the control individuals. Patients with tumor recurrence had significantly lower serum PON1 concentration than patients without tumor recurrence. The mean area under the curve of the receiver operating characteristics plot for serum PON1 concentration in discriminating patients with and those without tumor recurrence was 0.755 and the best combination of sensitivity and specificity was obtained at PON1 = 100 mg/L (0.72 and 0.80, respectively). Establishing this value as a cut-off, positive predictive value was = 0.91, and negative predictive value was = 0.50. These results suggest that the measurement of serum PON1 concentration may be a high-sensitivity marker of tumor recurrence in urinary bladder cancer patients.
本研究初步探讨了测量血清对氧磷酶 1(PON1)浓度和活性(以及其他炎症标志物)在预测膀胱癌患者肿瘤复发中的作用。我们共研究了 39 例经经尿道膀胱肿瘤切除术确诊为膀胱癌的住院患者。经过 5 年的随访,29 例患者出现肿瘤复发。作为对照组,我们还研究了 61 例健康受试者和 132 例因癌症以外的原因患有导尿管相关感染的住院患者。结果显示,与对照组相比,膀胱癌患者的血清 PON1 浓度和活性较低,趋化因子(C-C 基序)配体 2、C 反应蛋白和降钙素原浓度较高。与无肿瘤复发患者相比,肿瘤复发患者的血清 PON1 浓度显著降低。血清 PON1 浓度区分肿瘤复发和非肿瘤复发患者的受试者工作特征曲线下面积的平均值为 0.755,在 PON1=100mg/L 时获得了最佳的灵敏度和特异性组合(分别为 0.72 和 0.80)。将该值设定为截断值,阳性预测值为 0.91,阴性预测值为 0.50。这些结果表明,血清 PON1 浓度的测定可能是膀胱癌患者肿瘤复发的高灵敏度标志物。